97results about "Sonopheresis" patented technology

The present invention relates to an immunomicrobubble complex and its uses. The immunomicrobubble complex (IMC) according to the present invention comprises microbubbles conjugated with an antibody, wherein the microbubbles have excellent stability and excellent antibody binding strength, and it has been confirmed that when the immunomicrobubble complex is treated with high-intensity focused ultrasound (HIFU), the anti-tumor effect is significantly enhanced and an immune-enhancing effect is exhibited. Therefore, the immunomicrobubble complex according to the present invention is expected to improve the delivery efficiency of the conjugated antibody and can be used for the diagnosis and treatment of cancer, and exhibits various functions in the field of immunotherapy, including a contrast effect, improvement of half-life, improvement of drug delivery, lymphocyte concentrating effect, cancer immunotherapy, and ultrasound-induced immunotherapy.

The present invention relates to ultrasound (US) mediated delivery of therapeutic agents, such as the delivery of a drug, gene, nanoparticle or radioisotope, using a bi-phasic microparticle system comprising gas microbubbles, emulsion microdroplets and clusters thereof. Thus, the present invention relates to a cluster composition and a pharmaceutical composition, and their use for delivery of therapeutic agents and as a contrast agent for ultrasound imaging. It further relates to methods for delivering such therapeutic agents and to the use of said compositions.

Provided are methods, compositions, and kits for improving a delivery of a nucleic acid to a cell in an organ of a subject. Such methods, compositions, and kits may include a sonoactive agent and a nucleic acid comprising a cargo polynucleotide and a nuclear localization element and / or an innate immune response avoidance moiety, which may be an aptamer. Delivery may involve sonoporation.

An emulsion comprises a first discontinuous phase comprising first droplets, a second discontinuous phase comprising second droplets, and a continuous aqueous phase. The first droplets include at least one first surfactant and at least one first fluorocarbon, and have a first diameter of more than 100 nm. The second droplets include at least one surfactant, at least one drug, and at least one solvent, and have a second diameter of no more than 100 nm.

The present disclosure related to a method of using high frequency sound waves directed toward an acoustically active particle. The high frequency sound waves may be configured to enlarge the acoustically active particle and oscillate the acoustically active particle, thereby facilitating extravasation of an agent to a tissue compartment of a region of interest.

Provided is a multifunctional, multimodal, wearable platform device, including in the form of a patch, capable of delivering fluidic elements (including chemical compounds) through the skin to a subject in need thereof. The device is also capable of assisting in pain management via magnetic fields, electrical stimulation, kinetic energy, light energy, and other forms of non-chemical or non-pharmacological intervention.

A cholesterol oxidase-loaded biological material is a nanometer material and is characterized by comprising polyacrylic acid, cobalt oxyhydroxide and cholesterol oxidase, cobalt oxyhydroxide is adsorbed on polyacrylic acid to form a compound, and cholesterol oxidase is loaded on the compound. The size of the nano-biological material is about 100-150 nm, the nano-biological material is combined with ultrasound to obtain multiple nano-enzyme activities with enhanced effects and more excellent capabilities of generating active oxygen and relieving hypoxia, and a lipid raft structure on a cell membrane is damaged by the loaded cholesterol oxidase, so that cell migration is inhibited, and the effect of resisting tumor metastasis is achieved.

Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).

A method for controlling ultrasonic waves to induced sonoporation of a drug into cancer cells in a tumor. The method may include accessing configuration data that may include a type of the tumor and a type of drug, and determining values of operational parameters that may be based on the configuration data to define determined values. The operational parameters may include frequency value and duty cycle value. The method may also include determining frequency value which may be based on the type of tumor that may define a determined frequency value, and determining the duty cycle value which may be based on the type of drug and the type of tumor that may define a determined duty cycle value.

Methods for enhancing intracellular uptake of active agents by inducing temporary pore formation in a cell membrane are described. The methods generally comprise introducing nanoparticles to a cell in vivo, ex vivo, or in cell culture to magnetic nanoparticles that are taken up into the cell interior. The methods further comprise introducing active agents to the cell. A magnetic field is applied to the cell for targeted excitation of the internalized magnetic nanoparticles to induce temporary pore formation in the cell membrane, such that the active agent is taken up in an increased amount and / or at an increased rate by the cell.

The present invention relates to miRNA inhibitors for treating leiomyomas. In particular, it relates to inhibitors of one or more miRNAs selected from miR-148a-3p, miR-199a-5p and miR-33b-3p, which are used for treating uterine leiomyomas. The inhibitor is preferably an LNA-based oligonucleotide. A pharmaceutical composition comprising the inhibitor for treating uterine leiomyomas is also within the scope of the present invention.

The invention relates to the technical field of medicines, and discloses a preparation method and application of an amphiphilic high-molecular compound capable of being degraded by sound control. The amphiphilic high-molecular compound provided by the invention has good ultrasonic responsiveness through a specially designed ultrasonic response structure and an ultrasonic fracture structure, and can be decomposed under the ultrasonic action. The compound can be used for effectively wrapping the effective components of the medicine to form a medicine carrying system with ultrasonic responsiveness, so that targeted delivery and controllable release of the medicine are realized.

To allow a substance to pass through a cell membrane by increasing the permeability of the cell membrane, since a certain substance (e.g., a large molecule) that cannot normally traverse a cell membrane can be introduced into a cell by applying an alternating electric field to the cell for a certain period of time and the frequency of the alternating electric field is selected so that the application of the alternating electric field increases the permeability of the cell membrane, this approach being particularly beneficial in association with cancer cells (e.g., glioblastoma).SOLUTION: The first method comprises the steps of: applying an alternating electric field to a cell for a certain period of time, in which the application of the alternating electric field increases the permeability of a cell membrane; and introducing a substance near the cell, the increased permeability of the cell membrane allowing the substance to pass through the cell membrane.SELECTED DRAWING: None

Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).

Provided herein are methods of treating brain cancer in a subject, comprising evaluating one or more biological samples from a subject who has brain cancer for the presence of a miRNAs and administering interleukin-12 (IL-12); an immunogenic composition of human telomerase reverse transcriptase (hTERT), Wilms Tumor-1 (WT-1), and prostate specific membrane antigen (PSMA); and an anti-programmed cell death receptor 1 (PD-1) antibody to said subject if the subject has an increased expression level of the mIR-331-3p miRNA or isomiRs thereof and the miR-1537-3p miRNA or isomiRs thereof relative to a control population of subjects. Also provided herein are methods of treating brain cancer in a subject, comprising measuring an expression level of at least one mRNA biomarker selected from SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1, HOXD13, TGFβR3, UBA7, SFRP4, or any combination thereof, in a tumor sample from a subject and administering IL-12; an immunogenic composition hTERT, WT-1, and PSMA; and an anti-PD-1 antibody to said subject if the expression level of SYNGR3, OTX1, GABBR2, LHX1, CADM3, MLLT11, MNX1, GRB14, SLC34A2, PHYHIP, WNT10B, SLC17A6, CRLF1 and HOXD13 is decreased or if the expression level of TGFβR3, UBA7, SFRP4 is increased.

The invention discloses a drug-loaded microbubble and a preparation method and application thereof, the drug-loaded microbubble is of a shell membrane-cavity hollow microbubble structure, the shell membrane comprises a biodegradable polymer and lipid, the cavity contains a drug active component, and the drug active component is a biodegradable polymer. The active pharmaceutical ingredient comprises a part combined with the shell membrane and a part free in the cavity, and the part combined with the shell membrane accounts for 50% or less of the total mass of the active pharmaceutical ingredient. When the drug-loaded microbubbles release drugs, the parts dissociating in the cavities can be released in a short time, the local drug concentration is improved, and the treatment purpose is achieved.

A method for treatment of a vascular anomaly can include administering one or more sclerosing agents in a subject in need thereof, and using electric pulses to increase the permeability of cell walls.

To provide a vaccine comprising an antigen and IL-21.SOLUTION: Disclosed herein is a vaccine comprising an antigen and IL-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.SELECTED DRAWING: Figure 1

Disclosed herein is a vaccine comprising an antigen and IL-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.

The present invention relates to the technical field of pharmaceutical chemistry, and particularly relates to a zinc complex and its preparation method and application. The chemical structural formula of the zinc complex is As a sonosensitizer, it has the advantages of good biosafety, clear structure, and easy metabolism. Under the condition without ultrasound, its killing ability to cells is extremely small and the biosafety is good; under the condition of ultrasound irradiation, it can generate a large amount of singlet oxygen <supgt;1< / supgt;O<subgt;2< / subgt>, thereby destroying the intracellular redox balance, resulting in the death of cancer cells. Its IC50 value for 4T1 cells can reach 2.45 μM, showing excellent anti-tumor effects and is expected to be used in the sonodynamic therapy of tumors.

The present invention, based on a non-bubble-based sonoporation technique, provides an ultrasound-assisted delivery platform for drug-loaded chitosan nanoparticles. This platform comprises: the administration of drug-loaded chitosan nanoparticles and the application of ultrasound stimulation. The drug-loaded chitosan nanoparticles are delivered to a target site, where ultrasound waves are directly applied to induce cellular membrane deformation. The ultrasound mechanical force temporarily alters membrane permeability, thereby facilitating the intracellular delivery of the drug-loaded chitosan nanoparticles.

A method of treating a target tissue area with a ribosome-inactivating protein. The method comprises injecting the target tissue area with an effective dose of a ribosome-inactivating protein and administering electroporation therapy to the target tissue area.

Disclosed are methods of imaging a cancer cell, the method comprising applying a first alternating electric field at a first frequency to the cancer cell for a first period of time, wherein application of the first alternating electric field at the first frequency to the cancer cell for the first period of time increases permeability of cell membranes of the cancer cell; introducing a nanoparticle to the cancer cell, wherein the increased permeability of the cell membranes enables the nanoparticle to cross the cancer cell membrane; and imaging the cancer cell.

To provide a vaccine comprising an antigen and IL-21.SOLUTION: Disclosed herein is a vaccine comprising an antigen and IL-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.SELECTED DRAWING: Figure 1

A method for monitoring the viability of stem cell-derived cells used in stem cell therapy, comprising: introducing one or more stem cell-derived cells into a cell culture medium; introducing one or more nanoprobes into the cell culture medium, thereby transfecting the one or more stem cell-derived cells with the one or more nanoprobes; and detecting an optical signal from the one or more nanoprobes after transfection. The method may further comprise administering the one or more transfected stem cell-derived cells to a subject and detecting an optical signal from the one or more nanoprobes in vivo. The one or more stem cell-derived cells may comprise stem cells.

The invention discloses a drug delivery microneedle system driven by a miniature ultrasonic patch. The drug delivery microneedle system comprises an excitation circuit, the miniature piezoelectric ultrasonic patch, a drug carrying microneedle array, a coupling structure and a packaging structure. The system has a modulatable sound field characteristic, the excitation circuit drives the piezoelectric ultrasonic patch to generate ultrasonic vibration by applying an electric signal with specific frequency and amplitude, and release of a Janus kinase (JAK) inhibitor loaded by the microneedle array is promoted. The miniature ultrasonic patch adopts a sheet-shaped design, the size is 5-50mm, the thickness is 0.5-5mm, the working frequency is 0.1-4MHz, and the driving voltage is 40-100V. The main body material of the drug-loaded microneedle array is hydrogel capable of loading a JAK inhibitor, the microneedle substrate and the ultrasonic patch are tightly fixed through a coupling structure, and the ultrasonic patch is coated with a packaging structure. The controllability of the drug delivery microneedle is optimized by introducing the modulatable sound field, accurate regulation and control and synergism of drug release can be achieved, and the drug delivery microneedle has important application prospects in targeted therapy of immune skin diseases.

A novel localized, mechanical HIFU (LM-HIFU) transcatheter device that can ablate cancer cells and disrupt the stromal barrier in tumors, enhancing the efficacy of therapeutics and increasing immune cell infiltration. A miniaturized dual-lumen catheter device is configured to deliver M-HIFU to a tumor that does not have the anatomic limitations of conventional HIFU, and enables access to a primary or metastatic tumor regardless of the location.

Provided herein is an immunogenic composition comprising a synthetic antigen to COVID spike proteins, particularly the chimeric intermediate structure C-A Complex. Also disclosed herein is a method of preventing and / or treating a COVID infection in a subject in need thereof, by administering the immunogenic composition to the subject.

Certain substances (e.g., large molecules) that ordinarily cannot traverse the cell membrane of cells can be introduced into cells by applying an alternating electric field to the cell for a period of time, wherein the frequency of the alternating electric field is selected so that application of the alternating electric field increases permeability of the cell membrane. Once the permeability of the cell membrane has been increased, the substance is able to cross the cell membrane. This approach is particularly useful in the context of cancer cells (e.g., glioblastoma).

Disclosed herein are vaccines comprising an antigen and IL-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods can comprise administering the vaccine to the subject in need thereof.